Organ-on-Chip Technology Advances Preclinical Glioblastoma Research
Dynamic42 and Experimental Pharmacology and Oncology (EPO), both based in Germany, have announced a strategic collaboration to enhance preclinical models in brain cancer research. This partnership focuses on integrating organ-on-chip technologies into the core of preclinical drug development. By combining Dynamic42's organ-on-chip platforms with EPO's expertise in translational oncology, the collaboration aims to develop experimental setups that more accurately reflect human tumor biology. The initial projects target glioblastoma and the blood-brain barrier, utilizing Dynamic42's human-based BBB-on-chip model to explore therapeutic responses. This approach seeks to improve the reliability of data translation into clinical outcomes. 
